Agilon Health, Inc. (NYSE:AGL) Stock Has Average Price Target of $102.25 According to Analysts

Agilon Health, Inc. (NYSE:AGL) has earned an average recommendation of “Hold” from the fifteen brokerages that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $102.25.

Several brokerages have recently weighed in on AGL. Barclays set a $111.00 price target on shares of Agilon Health and gave the stock an “equal weight” rating in a research report on Thursday, August 6th. Wells Fargo & Company reissued an “overweight” rating and set a $146.00 price objective (up from $141.00) on shares of Agilon Health in a report on Tuesday, August 11th. Sanford C. Bernstein raised shares of Agilon Health from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $86.00 to $125.00 in a research note on Tuesday, September 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a report on Monday, August 24th. Finally, JPMorgan Chase & Co. increased their target price on Agilon Health from $31.00 to $85.00 and gave the company an “underweight” rating in a research report on Monday, August 24th.

Agilon Health Price Performance

AGL opened at $84.47 on Tuesday. The business has a fifty day moving average of $89.50 and a 200 day moving average of $78.88. The company has a quick ratio of 1.08, a current ratio of 1.08 and a debt-to-equity ratio of 0.07. The stock has a market cap of $1.42 billion, a P/E ratio of -5.92 and a beta of 2.98. Agilon Health has a 52-week low of $7.48 and a 52-week high of $133.04.

Agilon Health (NYSE:AGL) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $0.14 by $0.90. Agilon Health had a negative net margin of 3.92% and a negative return on equity of 119.38%. The company had revenue of $1.49 billion for the quarter, compared to the consensus estimate of $1.45 billion. As a group, sell-side analysts anticipate that Agilon Health will post -2.9 EPS for the current year.

Institutional Investors Weigh In On Agilon Health

Institutional investors have recently added to or reduced their stakes in the stock. Allworth Financial LP bought a new position in Agilon Health in the second quarter worth about $114,000. Proficio Capital Partners LLC purchased a new stake in shares of Agilon Health during the second quarter valued at about $210,000. The Manufacturers Life Insurance Company bought a new stake in shares of Agilon Health in the 2nd quarter valued at about $355,000. Integrated Wealth Concepts LLC bought a new stake in shares of Agilon Health in the 2nd quarter valued at about $384,000. Finally, Corient Private Wealth LP purchased a new position in shares of Agilon Health in the 2nd quarter worth approximately $406,000.

Agilon Health Company Profile

Agilon Health, Inc is a healthcare company that helps primary care physicians transition from traditional fee-for-service medicine to value-based care. The company primarily works with independent physician practices that serve older adults, particularly Medicare Advantage members, with the goal of improving care coordination, patient outcomes and the overall healthcare experience.

Agilon provides a technology and services platform designed to support population health management. Its offerings include data analytics, clinical and administrative workflows, practice management support, care coordination resources and assistance with payer contracting.